Heron Therapeutics, Inc.
HRTX
$0.34
$0.000.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 32.33% | -174.58% | 83.12% | -634.78% | -190.36% |
| Total Depreciation and Amortization | -14.56% | -1.49% | -12.68% | 0.65% | 10.89% |
| Total Amortization of Deferred Charges | 2.73% | 7.84% | 4.08% | -4.85% | -2.37% |
| Total Other Non-Cash Items | 6.66% | 35.51% | -85.43% | 434.98% | 22.36% |
| Change in Net Operating Assets | -114.42% | 132.90% | -349.07% | 130.36% | 17.09% |
| Cash from Operations | -43.70% | 83.23% | -790.01% | 112.25% | -22.53% |
| Capital Expenditure | 64.71% | -- | -- | 100.00% | -90.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -44.83% | 163.64% | -73.81% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -470.62% | 89.99% | -146.26% | 57.07% | 221.84% |
| Cash from Investing | -247.71% | 82.79% | -146.01% | 61.69% | 222.66% |
| Total Debt Issued | -- | -- | -103.37% | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 2,466.58% | 1,120.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -180.39% | -100.81% | 196.08% | -- | -- |
| Cash from Financing | 260.78% | -123.29% | -98.36% | 1,611.01% | 1,120.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.28% | 82.46% | -154.31% | 1,064.48% | 57.86% |